Double-blind, placebo-controlled study comparing the efficacy and safety of fexofenadine hydrochloride (120 and 180 mg once daily) and cetirizine in seasonal allergic rhinitis☆☆☆

Howarth, Peter H.; Stern, Martin; Roi, Larry D.; Reynolds, Robert F.; Bousquet, Jean

doi:10.1016/s0091-6749(99)70070-9

Cited by 148 publications

(98 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, other studies in adults with SAR have shown significant efficacy with fexofenadine in relieving all symptoms of SAR. 20,22,33 The effect of fexofenadine on nasal congestion might reflect an activity that is broader than its antagonism at the H 1 -receptor. Numerous in vitro studies with fexofenadine have highlighted the potential of this agent to produce significant anti-inflammatory effects at clinically relevant concentrations, [34][35][36][37][38] and it is hypothesized that these effects might contribute to inhibition of the late-phase response.…”

Section: Discussionmentioning

confidence: 99%

“…Large, randomized trials have been performed in adults to show the efficacy and safety of this agent in SAR. [20][21][22][23] Previous studies have shown that doses of fexofenadine HCl up to 60 mg 2 times per day (bid) are safe and well tolerated in children aged 6 through 11 years. 24,25 The present study was conducted to confirm the efficacy and safety of twice-daily dosing of fexofenadine HCl (30 mg bid) compared with placebo in the treatment of SAR in children.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Fexofenadine is efficacious and safe in children (aged 6-11 years) with seasonal allergic rhinitis

Wahn¹,

Meltzer²,

Finn³

et al. 2003

Journal of Allergy and Clinical Immunology

View full text Add to dashboard Cite

Background: This is the first prospective, randomized, doubleblind, placebo-controlled study showing statistical improvement of an H 1 -antihistamine in children with seasonal allergic rhinitis in all symptoms throughout the entire treatment period. Objective: This randomized, placebo-controlled, parallelgroup, double-blind study was performed to assess the efficacy and safety of fexofenadine in children with seasonal allergic rhinitis. Methods: This study was conducted at 148 centers in 15 countries. Nine hundred thirty-five children (aged 6-11 years) were randomized and treated with either fexofenadine HCl 30 mg (n = 464) or placebo (n = 471) tablets twice a day for 14 days. Individual symptoms (sneezing; rhinorrhea; itchy nose, mouth, throat, and/or ears; itchy, watery, and/or red eyes; and nasal congestion) were assessed at baseline and then daily at 7:00 AM and 7:00 PM (±1 hour) during the double-blind treatment period. Each total symptom score was the sum of all symptoms, excluding nasal congestion. The primary efficacy variable was the change from baseline in the average of the daily 12-hour evening reflective total symptom scores throughout the double-blind treatment. Safety was evaluated from adverse-event reporting, vital signs, physical examinations, and clinical laboratory data at screening and study end point.Results: Fexofenadine was significantly superior to placebo in the primary efficacy analysis (P ≤ .0001). Individual symptom scores showed statistically significant superiority compared with placebo (P < .05), including nasal congestion in the evening reflective assessment (P < .05). There was no significant difference in adverse events between fexofenadine and placebo, either overall or by causality.

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

Fexofenadine is efficacious and safe in children (aged 6-11 years) with seasonal allergic rhinitis

Wahn¹,

Meltzer²,

Finn³

et al. 2003

Journal of Allergy and Clinical Immunology

View full text Add to dashboard Cite

show abstract

“…Newer antihistamines induce no (1461,1468,(1541)(1542)(1543) or little sedation or impairment (1066,1544). They are not anticholinergic.…”

Section: 22mentioning

confidence: 99%

Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*

Bousquet¹,

Khaltaev²,

Cruz³

et al. 2008

Allergy

3,801

1,761

View full text Add to dashboard Cite

“…Second-generation antihistamines, e.g. acrivastine, cetirizine, desloratadine, fexofenadine levocetirizine, loratadine and mizolastine are less sedating in most patients, with fexofenadine the least sedating [73,74]. In addition, they do not cause significant QT prolongation at normal therapeutic doses have few major drug interactions, except for increased risk of ventricular arrhythmias, when mizolastine is co-administered with some antiarrhythmics, antibiotics and b-blockers.…”

Section: Adverse Eventsmentioning

confidence: 99%

BSACI guidelines for the management of allergic and non‐allergic rhinitis

Scadding

Durham

Mirakian

et al. 2007

Clin Experimental Allergy

348

292

View full text Add to dashboard Cite

SummaryThis guidance for the management of patients with allergic and non-allergic rhinitis has been prepared by the Standards of Care Committee (SOCC) of the British Society for Allergy and Clinical Immunology (BSACI). The guideline is based on evidence as well as on expert opinion and is for use by both adult physicians and paediatricians practicing in allergy. The recommendations are evidence graded. During the development of these guidelines, all BSACI members were included in the consultation process using a web-based system. Their comments and suggestions were carefully considered by the SOCC. Where evidence was lacking, consensus was reached by the experts on the committee. Included in this guideline are clinical classification of rhinitis, aetiology, diagnosis, investigations and management including subcutaneous and sublingual immunotherapy. There are also special sections for children, co-morbid associations and pregnancy. Finally, we have made recommendations for potential areas of future research.

show abstract

Double-blind, placebo-controlled study comparing the efficacy and safety of fexofenadine hydrochloride (120 and 180 mg once daily) and cetirizine in seasonal allergic rhinitis☆☆☆

Cited by 148 publications

References 15 publications

Fexofenadine is efficacious and safe in children (aged 6-11 years) with seasonal allergic rhinitis

Fexofenadine is efficacious and safe in children (aged 6-11 years) with seasonal allergic rhinitis

Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*

BSACI guidelines for the management of allergic and non‐allergic rhinitis

Contact Info

Product

Resources

About